Results from a multi-institutional study led by a Cleveland Clinic researcher, DCSionRT®, a biosignature based on multiple biomarkers, may hold the key to solving the treatment of ductal carcinoma in situ (DCIS). Chirag Shah, MD, coinvestigator, and director of Breast Radiation Oncology at Cleveland Clinic joins the Cancer Advances podcast to explain the study and findings that were presented at the American Society for Radiation Oncology annual meeting (ASTRO).
view more